ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,575.80 ▲ 15.00 (0.96%)ENR.DE: $162.00 ▼ -0.50 (-0.31%)GLEN.L: $537.80 ▲ 2.50 (0.47%)IFX.DE: $81.29 ▲ 0.73 (0.91%)NOKIA.HE: $12.15 ▲ 0.15 (1.25%)RIO.L: $7,287.00 ▲ 23.00 (0.32%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

MaxCyte, Inc.

MXCT - NASDAQ

Identifiants & Marche

Ticker MXCT
ISIN US57777K1060
CIK 0001287098
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.